The antibody drug conjugates market was valued at $1,387 million in 2016, and is estimated to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023. Antibody drug conjugates (ADC’s) are promising and effective anticancer medications employed for efficient treatment of cancer patients. ADC’s are biopharmaceutical drugs prepared by integrating two clinical approaches viz cell killing HPAPI (powerful pharmaceutical ingredient) and monoclonal antibody specificity. This combination approach enables elimination of cancer infected cells without harming healthy cells in patient’s body.
Increase in global prevalence of cancer and demand for quality & cost-effective cancer medications drives the global ADCs market. In addition, extensive R&D for cancer medication and approval of new cancer drugs is expected to boost the market growth during the forecast period. However, high cost involved in R&D of cancer medication and stringent government regulations impedes the growth of antibody drug conjugates market.
The report segments the market based on drugs, mechanism of action, application, and region. Based on drugs, the market is bifurcated into Adcetris and Kadcyla. Based on mechanism of action, it is divided into CD30 antibodies and HER2 antibodies. Based on application, the market is classified into breast cancer, lymphoma, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS
KEY PLAYERS PROFILED
KEY MARKET SEGMENTS
BY MECHANISM OF ACTION
The other players of the anesthesia market include (companies not profiled in the report):
Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep ...
November 2017 | $5370 |View Details>>
The Global Drugs for Malaria market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Drugs for Malaria market, especially in North America, Europe, Asia-Pacific, South ...
November 2017 | $4960 |View Details>>
In 2016, the Asia-Pacific Drugs for Malaria market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Drugs for Malaria in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and ...
November 2017 | $4660 |View Details>>
In 2016, the Drugs for Malaria market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include Cipla Guilin Pharmaceutical ...
November 2017 | $3360 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research